BackgroundPersistence of anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis (RA) is an
overall marker of treatment success.ObjectiveTo assess the survival of anti-TNF treatment and to define the potential predictors of drug
discontinuation in RA, in order to verify the adequacy of current practices.DesignAn observational, descriptive, longitudinal, retrospective study.SettingThe Hospital Clínico Universitario de Valladolid, Valladolid, Spain.PatientsRA patients treated with anti-TNF therapy between January 2011 and January 2012.MeasurementsDemographic information and therapy assessments were gathered from medical and pharmaceutical
records. Data is expressed as means (standard deviations) for quantitative variables and frequency
distribution for qualitative variables. Kaplan–Meier survival analysis was used to assess
persistence, and Cox multivariate regression models were used to assess potential predictors of
treatment discontinuation.ResultsIn total, 126 treatment series with infliximab (n = 53), etanercept (n = 51) or adalimumab (n =
22) were administered to 91 patients. Infliximab has mostly been used as a first-line treatment, but
it was the drug with the shortest time until a change of treatment. Significant predictors of drug
survival were: age; the anti-TNF agent; and the previous response to an anti-TNF drug.LimitationThe small sample size.ConclusionThe overall efficacy of anti-TNF drugs diminishes with time, with infliximab having the shortest
time until a change of treatment. The management of biologic therapy in patients with RA should be
reconsidered in order to achieve disease control with a reduction in costs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.